| Title: | Potentiation of electrochemotherapy effectiveness by immunostimulation with IL-12 gene electrotransfer in mice is dependent on tumor immune status |
|---|
| Authors: | ID Uršič Valentinuzzi, Katja (Author)
ID Kos, Špela (Author)
ID Kamenšek, Urška (Author)
ID Čemažar, Maja (Author)
ID Miceska, Simona (Author)
ID Markelc, Boštjan (Author)
ID Buček, Simon (Author)
ID Starešinič, Barbara (Author)
ID Kloboves-Prevodnik, Veronika (Author)
ID Heller, Richard (Author)
ID Serša, Gregor (Author) |
|---|
| Files: |  PDF - Presentation file, download (7,82 MB)
MD5: 53FD7CD78C93640F8B5DBCA4938228C4
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  OI - Institute of Oncology
|
|---|
| Abstract: | Electrochemotherapy (ECT) exhibits high therapeutic effectiveness in the clinic, achieving up to 80% local tumor control but without a systemic (abscopal) effect. Therefore, we designed a combination therapy consisting of ECT via intratumoral application of bleomycin, oxaliplatin or cisplatin with peritumoral gene electrotransfer of a plasmid encoding interleukin-12 (p. t. IL-12 GET). Our hypothesis was that p. t. IL-12 GET potentiates the effect of ECT on local and systemic levels and that the potentiation varies depending on tumor immune status. Therefore, the combination therapy was tested in three immunologically different murine tumor models. In poorly immunogenic B16F10 melanoma, IL-12 potentiated the antitumor effect of ECT with biologically equivalent low doses of cisplatin, oxaliplatin or bleomycin. The most pronounced potentiation was observed after ECT using cisplatin, resulting in a complete response rate of 38% and an abscopal effect. Compared to B16F10 melanoma, better responsiveness to ECT was observed in more immunogenic 4%T1 mammary carcinoma and CT26 colorectal carcinoma. In both models, p. t. IL-12 GET did not significantly improve the therapeutic outcome of ECT using any of the chemotherapeutic drugs. Collectively, the effectiveness of the combination therapy depends on tumor immune status. ECT was more effective in more immunogenic tumors, but GET exhibited greater contribution in less immunogenic tumors. Thus, the selection of the therapy, namely, either ECT alone or combination therapy with p. t. IL-12, should be predominantly based on tumor immune status. |
|---|
| Keywords: | electrochemotherapy, gene electrotransfer, interleukin-12 |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Publication date: | 08.03.2021 |
|---|
| Publisher: | Elsevier |
|---|
| Year of publishing: | 2021 |
|---|
| Number of pages: | str. 623-635 |
|---|
| Numbering: | Vol. 332, no. 21 |
|---|
| PID: | 20.500.12556/DiRROS-15569  |
|---|
| UDC: | 602.6/.7 |
|---|
| ISSN on article: | 0168-3659 |
|---|
| DOI: | 10.1016/j.jconrel.2021.03.009 |
|---|
| COBISS.SI-ID: | 54492931 |
|---|
| Copyright: | by Authors |
|---|
| Publication date in DiRROS: | 21.09.2022 |
|---|
| Views: | 1048 |
|---|
| Downloads: | 373 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
